Nucleic acid sequences having characteristics of enhanced expression in human neuroblastoma with favorable prognosis based on comparison between human neuroblastoma with favorable prognosis and human neuroblastoma with unfavorable prognosis

• US 20060188919A1
• Filed: 04/18/2006
• Published: 08/24/2006
• Est. Priority Date: 03/07/2000
• Status: Active Grant

• Current Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Original Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Inventors: Nakagawara, Akira
• Granted Patent: US 7,384,750 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/47 from mammals

Abstract

There are disclosed a nucleic acid which is derived from the gene expressed in human neuroblastoma, and which comprises any sequence selected from the group consisting of the nucleic acid sequences set forth SEQ ID NO:1 to NO:104 in the Sequence Listing, or its complementary nucleic acid; a fragment of the nucleic acid; their use as probes or primers; and the diagnosis of neuroblastoma prognosis using any of the foregoings.

Claims

1. An isolated nucleic acid derived from a gene expressed in human neuroblastoma, the isolated nucleic acid comprising a sequence selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:

1 to NO;

104 in the Sequence Listing, or a complementary nucleic acid thereof.

11. An isolated nucleic acid according to claim 1, wherein said isolated nucleic acid comprises a sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:

4, SEQ ID NO;

12, SEQ ID NO;

21, SEQ ID NO;

24, SEQ ID NO;

26, SEQ ID NO;

27, SEQ ID NO;

30, SEQ ID NO;

35, SEQ ID NO;

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

39, SEQ ID NO;

48, SEQ ID NO;

56, SEQ ID NO;

57, SEQ ID NO;

61, SEQ ID NO;

65, SEQ ID NO;

71, and SEQ ID NO;

77 in the Sequence Listing or a complementary nucleic acid thereof.

12. The isolated nucleic acid according to claim 11, wherein the nucleic acid is DNA.

13. A hybridization probe for a nucleic acid according to claim 11, wherein the probe comprises a 40 or more contiguous sequence of the nucleic acid according to claim 11 or a complementary nucleic acid according to claim 11.

14. A PCR primer for the nucleic acid according to claim 11, wherein the primer comprises a 15 to 30 contiguous sequence of the nucleic acid according to claim 11 or a complementary nucleic acid according to claim 11.

2-10. -10. (canceled)

15. A method of diagnosing the prognosis of human neuroblastoma, said method comprising

extracting a neuroblastoma specimen from a subject;

detecting at least one nucleic acid in the specimen, the nucleic acid comprising a sequence selected from the group consisting of nucleic acid sequences set forth in the Sequence Listing or a complementary nucleic acid thereof; and

diagnosing the prognosis of the human neuroblastoma as favorable if said nucleic acid is detected.

16. The method according to claim 16, wherein said nucleic acid comprises SEQ ID NO:

4, SEQ ID NO;

12, SEQ ID NO;

21, SEQ ID NO;

24, SEQ ID NO;

26, SEQ ID NO;

27, SEQ ID NO;

30, SEQ ID NO;

35, SEQ ID NO;

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

39, SEQ ID NO;

48, SEQ ID NO;

56, SEQ ID NO;

57, SEQ ID NO;

61, SEQ ID NO;

65, SEQ ID NO;

71, and SEQ ID NO;

77 in the Sequence Listing or a complementary nucleic acid thereof.